Last reviewed · How we verify
Ezatiostat Hydrochlorine
Ezatiostat Hydrochlorine is a Small molecule drug developed by Telik. It is currently in Phase 1 development. Also known as: TLK199 Tablets, Telintra.
At a glance
| Generic name | Ezatiostat Hydrochlorine |
|---|---|
| Also known as | TLK199 Tablets, Telintra |
| Sponsor | Telik |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ezatiostat Hydrochlorine CI brief — competitive landscape report
- Ezatiostat Hydrochlorine updates RSS · CI watch RSS
- Telik portfolio CI
Frequently asked questions about Ezatiostat Hydrochlorine
What is Ezatiostat Hydrochlorine?
Ezatiostat Hydrochlorine is a Small molecule drug developed by Telik.
Who makes Ezatiostat Hydrochlorine?
Ezatiostat Hydrochlorine is developed by Telik (see full Telik pipeline at /company/telik).
Is Ezatiostat Hydrochlorine also known as anything else?
Ezatiostat Hydrochlorine is also known as TLK199 Tablets, Telintra.
What development phase is Ezatiostat Hydrochlorine in?
Ezatiostat Hydrochlorine is in Phase 1.
Related
- Manufacturer: Telik — full pipeline
- Also known as: TLK199 Tablets, Telintra
- Compare: Ezatiostat Hydrochlorine vs similar drugs
- Pricing: Ezatiostat Hydrochlorine cost, discount & access